Bfsg LLC Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Bfsg LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 18.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,992 shares of the company’s stock after buying an additional 16,375 shares during the quarter. Novo Nordisk A/S comprises about 1.0% of Bfsg LLC’s holdings, making the stock its 22nd biggest holding. Bfsg LLC’s holdings in Novo Nordisk A/S were worth $8,859,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of NVO. Natixis Advisors LLC increased its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC grew its position in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $86,000. Talbot Financial LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $4,066,000. Finally, Clear Creek Financial Management LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $450,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.1 %

Shares of Novo Nordisk A/S stock opened at $77.94 on Tuesday. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The business’s fifty day moving average is $88.65 and its two-hundred day moving average is $109.54. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $349.75 billion, a PE ratio of 23.69, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 21.88%.

Wall Street Analyst Weigh In

A number of research analysts have commented on NVO shares. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.